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Abstract 
Background:  
The most common neurological manifestation of APS is ischaemic stroke. 
Identifying patients with APS at high risk for developing any thrombotic event 
remains a major challenge.  In this study, we aimed to identify predictive factors 
of ischaemic stroke in a cohort of primary APS (PAPS) patients who presented 
with new onset symptoms suggestive of acute stroke. 
Methods:  
This prospective multicenter study included 36 consecutive PAPS patients who 
presented with new onset symptoms suggestive of an acute stroke. Patients 
were prospectively followed-up for 12months. 
Results:  
In ten (28%) out of 36 PAPS patients [mean age 41 years old (S.D.13.4), female 
(70%)], the suspicion of an acute stroke was confirmed by brain MRI. Sixty 
percent of these patients were <50 years old. Six out of the ten patients had a 
history of previous venous thrombosis and were receiving vitamin K antagonist 
(VKA), with INR target 2-3; one patient had a history of a previous arterial event 
receiving treatment with VKA target INR 2-3 plus low dose aspirin (LDA), and 
one patient had a history of previous pregnancy morbidity receiving only LDA. 
Time in therapeutic range for patients receiving VKA was 77.7 (S.D.6.6). 
Hypercholesterolemia was significantly higher in patients with confirmed stroke 
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when compared to those without (p<0.05). Similarly, we found a significantly 
higher rate of anti-ß2GPI antibodies (IgG/IgM)(p<0.05) and higher aGAPSS 
values in patients with a confirmed stroke [mean aGAPSS 8.9(S.D.4.7) Vs. mean 
aGAPSS6.4(S.D.2.5);p:<0.05]. 
Conclusions:  
Patients with PAPS, including young patients, have a high risk of recurrent 
thrombosis despite anticoagulation treatment. A careful risk assessment is 
mandatory to identify patients at risk for recurrence.  
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1.1 Introduction 
The antiphospholipid syndrome (APS), recognized as the  most common 
acquired thrombophilia, is an autoimmune condition characterized by the 
occurrence of thrombotic events and/or pregnancy morbidity in individuals 
found to be persistently positive for antiphospholipid antibodies (aPL) [1]. The 
current classification criteria for APS include three laboratory tests: lupus 
anticoagulant (LA), anti-cardiolipin (aCL), and anti-β2 glycoprotein-I (β2GPI) 
antibodies. To prevent the detection of transient antibodies, tests must be 
positive on two separate  occasions, at least 12 weeks apart [1]. APS can be 
associated with another autoimmune disease, mainly systemic lupus 
erythematosus, and has in the past been described as 'secondary' APS. On the 
other hand, APS can be found as an isolated condition called 'primary' APS 
(PAPS). 
Thrombotic events in APS can affect the venous and the arterial system [1]. 
While deep vein thrombosis represents the most frequent thrombotic feature of 
APS,  arterial events include the potentially most life-threatening manifestations 
of the syndrome, being the central nervous system the most common affected 
site [2,3]. Ischaemic stroke involving the territory of the middle cerebral artery 
is the main neurological manifestation associated with APS [2]. However, 
transient ischaemic attack (TIA), amaurosisfugax, transient paresthesias, 
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cerebral venous sinus thrombosis, ocular ischaemia, and acute ischaemic 
encephalopathy have been also described [2,4].  
Considering all patients with cerebral ischaemic events, the prevalence of aPL in 
young adults below the age of 50 has been reported as high as 17·2% (range 
2%–56%)[5]. Given their young age and how the development of 
cerebrovascular events can negatively influence the quality of life, patients with 
aPL positivity represents a particular subgroup at greater risk of developing 
serious stroke and in which the development of risk stratification models is 
necessary [5]. 
To date, identifying patients with aPL positivity who are at high risk for 
developing any thrombotic event, including cerebrovascular manifestations, is 
still an unmet clinical need and remains a major challenge for the treating 
physicians.   
Recently, our group developed a risk score for clinical manifestations of APS [the 
global APS score (GAPSS)] that takes into account the combination of 
conventional risk factors for cardiovascular events and the aPL  profile[6].  
In this study, we aimed to prospectively identify predictive factors of ischaemic 
stroke in a cohort of PAPS patients with a clinical suspicion of acute stroke event 
and to further evaluate the rate of recurrence and/or progression of cerebral 
lesions and potential new subclinical signs of infarction after 12 months of 
follow-up. 
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2.1 Patients and methods:   
2.2 Patients 
This prospective multicenter study included 36 consecutive patients with 
known history of PAPS (either previous arterial or venous thrombotic events or 
pregnancy morbidity) attending the Giovanni Bosco Hospital, Turin, Italy and 
the Louise Coote Lupus Unit at St Thomas’ Hospital, London, UK who presented 
with a new episode clinically suggestive of an acute stroke to our departments 
or the emergency departments within our hospitals (enrollment time January 
2015-February 2017). The decision to conduct brain imaging was initiated by 
the emergency physician and it was based on the suspicion of an acute stroke. 
Every patient was additionally clinically assessed by a neurologist as per 
standard of care in our two centers. 
Study inclusion criteria comprehend: a) the diagnosis of PAPS according to 
Sidney criteria [1], b) the onset signs and/or symptoms of new focal 
neurological deficits suggestive of an acute stroke evaluated by a neurologist. 
The indication for performing the MRI was the suspicion of an acute 
cerebrovascular event following the National Institute for Health and Care 
Excellence (NICE) guidelines based on the onset of new focal neurological 
deficits [7]. The presence of concomitant or any previous history of headaches 
(including migraines with and without aura), cognitive impairment, and self-
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reported word finding difficulties were recorded. The assessment for cerebral 
events included brain computed tomography, MRI, carotid ultrasound, 
electrocardiogram, and echocardiography. Imaging findings were discussed in 
multidisciplinary meetings.  
At admission, patients in the stroke group were screened for alternative 
etiologies (e.g.  substance abuse, carotid/vertebral artery dissections and cardio-
embolic etiology). In detail, after an initial brain MRI to confirm the ischeamic 
event, neck and cerebral vascular imaging (e.g., CTA for head and neck), 
transthoracic echocardiogram with a bubble study, additional risk factor blood 
work (e.g., TSH, ESR, CRP, HIV, and toxicology screen), and, when appropriate, 
sickle screen and pregnancy test where performed according treating 
physician’s judgment.  
Patients were followed-up for 12 months. A follow-up cerebral MRI was 
performed after 12 months in all patients to assess the outcome of the abnormal 
findings reported in the first brain MRI and to investigate potential new 
subclinical signs of infarction. 
Demographic, clinical and laboratory characteristics are summarized in Table 1. 
2.3 Cardiovascular risk factors assessment 
Cardiovascular risk factors of the study population were assessed following the 
NICE guidelines [8]. In detail, enrolled patients underwent a physical 
examination, blood pressure determination, and phlebotomy in order to assess 
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vascular risk factors. Arterial hypertension was defined as an appropriately 
sized cut-off [8], high blood pressure on at least two occasions, and/or use of 
oral antihypertensive medications. Serum total and high-density lipoprotein 
cholesterol levels were determined according to standardized methods and 
interpreted according to current cut-off values [8]. 
Autoantibody detection 
The aPL profile included LA, aCL, and anti-ß2GPI antibodies. The aCL and anti-
ß2GPI were detected by ELISA as described previously [9,10]. Plasma samples 
were tested for the presence of LA according to the recommended criteria from 
the International Society on Thrombosis and Haemostasis (ISTH) Subcommittee 
on Lupus Anticoagulant/Phospholipid-Dependent Antibodies [11,12] 
2.4 Adjusted GAPSS calculation 
The cumulative aGAPSS was calculated for each patient as previously reported, 
by adding together all points corresponding to the risk factors [6,13]. After its 
first description, GAPSS was prospectively validated [14] and applied in a cohort 
of patients with PAPS [15]. To increase the generalizability of the findings, in this 
study we applied an adjusted version of GAPSS (aGAPSS). This comprises only 
aPL testing included in the current classification criteria for APS (excluding aPS-
PT, not routinely available in all the laboratories). Data are presented as aGAPSS. 
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For the purpose of this study, all computed variables refer to values/parameters 
assessed at the time of the suspected stroke and after 12 months of follow up.  
2.5 Statistical analysis 
Categorical variables are presented as number (%) and continuous variables are 
presented as mean (S.D.). The significance of baseline differences was 
determined by the chi-squared test, Fisher’s exact test or the unpaired t-test, as 
appropriate. A two-sided P-value <0·05 was statistically significant. All statistical 
analyses were performed using SPSS version 19.0 (IBM, Armonk, NY, USA).  
3.1 Results:  
A total of 36 consecutive PAPS patients [mean age 32 years old (SD 33.7), female 
(86%)] with suspect stroke were included in this prospective study. Twenty-five 
patients (69%) were <50 years old at the time of the first event. All patients 
fulfilled the current classification criteria for PAPS.  
New focal neurological deficits were distributed as follows: six with dysphasia or 
dysarthria, four with self-reported speech disturbance, eight with subjective arm 
or leg weakness, 13 with subjective arm or leg paresthesia and 16 with new 
onset of severe headache.  
3.2 Ischaemic Stroke  
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In ten patients (28%) [mean age 41 years old (SD 13.4), female (70%)] the 
suspicion of an acute ischaemic stroke was confirmed and MRI findings were 
compatible with a new ischaemic lesion. Demographics, cardiovascular risk 
factors, and aPL profile at the time of the stroke are summarized in Table 2. In 
the remaining 26 patients, the diagnosis of ischaemic stroke was ruled out after 
clinical and imaging evaluation.  
When analyzing for cardiovascular risk factors, hypercholesterolemia was 
significantly higher in the patients with confirmed stroke when compared to 
those without (Chi square test: p< 0.05). No evidence of clinical significant large-
artery atherosclerosis nor cardio-embolic etiology was found in the 10 cases of 
ischemic cerebrovascular events. Similarly, when evaluating the aPL positivity 
profiles in these two distinct groups, we found a significantly higher rate of anti-
ß2GPI antibodies (IgG/IgM) in patients with stroke (Chi square test: p<0.05). 
However, when focusing on the so-called triple positivity, we failed to observe 
any statistical difference (Table 2).  
Significantly higher aGAPSS values were seen in patients with stroke [mean 
aGAPSS 8.9 (S.D. 4.7) Vs. mean aGAPSS 6.4 (S.D. 2.5); T test p:<0.05]. 
No statistical significant differences were observed when comparing separately 
each cardiovascular risk factor (i.e. smoking, diabetes, arterial hypertension) nor 
other thrombotic risk factors (hormonal therapy, immobilization, surgery or 
malignancy). 
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Due to previous thrombosis, 25 patients were receiving oral anticoagulation 
with vitamin-K antagonists (VKA). Of those 25 patients, 20 patients suffered 
previous DVT and were treated with VKA with a target INR:2-3; Out of five 
patients with previous arterial thrombosis, three were treated with VKA  with a 
target INR of 2-3 plus LDA, and two patients with VKA and a target INR 
between3-4. Moreover, three patients were treated with low molecular weight 
heparin (LMWH) (two patients because of pregnancy and one patient for 
secondary thromboprophylaxis whilst treated with chemotherapy for breast 
cancer). Eight patients with a previous history of obstetric APS were receiving 
anti-platelets agents. 
Out of the 10 patients in whom the suspected stroke was confirmed, six had a 
history of previous venous thrombosis and were receiving VKA, INR target 2-3, 
one patient had a history of an arterial event and was treated with VKA INR 2-3 
plus low dose aspirin (LDA) and one patient had a history of previous pregnancy 
complication and received LDA. For patients receiving therapy with VKA, the 
mean time in therapeutic range (TTR) calculated over the previous six months 
before the new cerebrovascular event was 77.7 (S.D. 6.6). 
A tight control of cardiovascular risk factors and treatment implementation with 
statins and/or anti-hypertensive agent was ensured for all the patients and 
monitored by the treating physician’s judgment. Therapeutic goals were set 
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according to current recommendations [16,17]. 3.3. Evaluation at 12 Months 
of follow-up 
During the 12 months of follow-up, no patient developed new episodes clinically 
suggestive of cerebral ischemia. In the non-stroke group, no changes at the 
follow-up MRI were observed when compared to baseline investigation.  
After the diagnosis of stroke, 9/10 patients were started/continued on 
anticoagulation therapy with VKA INR 2-3 plus LDA. The patient with previous 
arterial event was continued on VKA, increasing the INR target to 3-4. In 
agreement with the stroke unit team, one patient (with previous history of 
obstetric APS and subsequent stroke) was initially treated with VKA plus LDA 
but had to be switched to dual anti-platelet agents (LDA+Clopidogrel) after three 
months of VKA treatment because of unsatisfactory TTR, poor compliance and 
adherence on medical appointments.  
After 12 months of follow-up, the 9 patients on VKA treatment showed no sign of 
cerebral progression based on new brain MRI. VKA was well tolerated and no 
adverse event was reported.  
The one patient only treated with anti-platelet agents presented progression of 
the cerebral lesions as assessed after multidisciplinary panel evaluation. More 
specifically, at the brain MRI exam, a significant progression of the previously 
known lacunar infarctions involving the posterior limb of the left internal 
capsule/lateral thalamus and left frontal subcortical white matter was observed.  
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Other cardiovascular risk factors were managed according to treating 
physician’s judgment. 4.1 Discussion:   
This prospective multicenter study assesses predictive factors for stroke in a 
cohort of 36 PAPS patients presenting with the onset of signs and/or symptoms 
of new focal neurological deficits suggestive of an acute stroke. 
We found that ten patients (28%) had a confirmed diagnosis of acute ischaemic 
cerebrovascular event. When stratifying patients for age, we found that 6/10 
patients with a documented stroke at the brain MRI scan belonged to the 
younger subgroup of patients (<50 years old). Moreover, patients who 
experienced a stroke were receiving treatment according to the current 
recommendations. TTR for those patients treated with VKA as secondary 
thromboprophylaxis was 77.7%.  
Our results highlight the fact that despite being treated with anticoagulation 
(VKA treatment), patients with thrombotic PAPS still represent a sub-group of 
patients at high risk for thrombosis recurrences.  
The identification of patients with aPL, who are at greater risk for developing 
any thrombotic event, i.e. especially arterial cerebral thrombosis, is still an 
unmet need. Therefore, risk stratifying in these patients remains crucial in this 
very setting.  
In our prospective study, we demonstrate the clinical relevance of the aGAPSS 
for risk stratification in PAPS patients with stroke. In fact, significantly higher 
14 
 
values of aGAPSS were found in patients with stroke. Those results are in line 
with a very recent study from our group, showing higher aGAPSS values in 
patients who experienced acute myocardial infarction when compared to those 
with other thrombosis[18].  
Recently, a variety of prediction models for cardiovascular disease have been 
developed mainly focusing on stroke or ischaemic heart events. Among others, 
Hajifathalian and colleagues [19] elaborated a well thought out cardiovascular 
disease risk equation (Globorisk), adjusted for country origin, with routinely 
available information. Their risk score is based primarily on age, country of 
origin, arterial hypertension, smoking, and diabetes. Although promising, such 
score does not seem applicable to patients with autoimmune disorders, 
especially a rare disorder such as PAPS. As a matter of fact, in our cohort 15 
patients out of 36 (42%) were younger than 40 years old and the Globoriskcan 
therefore not be applied. Furthermore, just a portion of patients had diabetes (2 
out of 36; 6%) and/or arterial hypertension (9 out of 36; 25%). 
While anti-platelet agents are the gold standard therapies in stroke, patients 
with APS have been shown to benefit from long term anticoagulation [20]. 
Indeed, the only patient in our cohort who suffered with a progression of the 
ischaemic cerebral lesion at MRI, after 12 months follow up, was the one not 
treated with VKA.   
When referring to the putative etiology of the stroke, patients were screened 
according treating physician’s judgment and no significant causes rather than 
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the presence of aPL and the described CV risk factors were identified. It was out 
of the scope of this study to assess the clinical accuracy of previously proposed 
systems for the etiological classification of ischemic stroke in patients with aPL 
(e.g. TOAST, CCS and ASCO systems [21–23]) . However, patients with confirmed 
events could be categorized as having “acute stroke of other determined 
etiology” according to the TOAST classification [21], as this category includes 
patients with more rare causes of stroke, such as non-atherosclerotic 
vasculopathies or hypercoagulable states, or hematologic disorders. 
This study presents some limitations. First, the sample size is small, mainly due 
to the low prevalence of PAPS in the general population. Secondly, anticoagulant 
treatments before the cerebrovascular event and other cardiovascular risk 
factors treatment was based on the treating physician’s judgment. Thirdly, 
previous medical history of PAPS patients was heterogeneous, including venous 
and arterial thrombosis and obstetric APS.   
5. Summary 
In summary, we think this study, acknowledging its limitations, contains some 
important clinical messages: PAPS is a thrombophilia with a high rate of 
recurrences; cerebrovascular events such as stroke affect a younger population 
when compared with non-APS population; a risk assessment, using appropriate 
tools such as aGAPSS, should be implemented to identify those patients at a 
higher risk of recurrences and have a strict control of all modifiable risk factors 
for cardiovascular events. 
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